NASDAQ · SERVICES-MEDICAL LABORATORIES
Caris Life Sciences, Inc. CAI
3 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$812.0M
▲ 97.0% vs FY2024
EPS · FY25
$-3.22
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
—
Net margin · FY25
-8.4%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 812.0M
Revenue, FY2025 · full 3-year series below
Revenue
Net income
The company lost 8 cents on every revenue dollar this year.
Per share
USD -3.22
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
—
Return on equity, FY2025
ROE
Operating margin5.6%
Net margin-8.4%
Return on assets-9.3%
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacksUSD -7.5M
Share of profit-0.0%
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.28B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 1.1B
total assets, end of FY2025
Total assetsUSD 1.1B
EquityUSD 577.3M
CashUSD 796.3M
Gross debtUSD 379.0M
Net debtUSD -417.3M
Current ratio7.85×
The company holds more cash than debt.
History
3 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
Revenue $B
0.8
0.4
0.3
Operating income $B
0.0
−0.3
−0.3
EBITDA $B
0.1
−0.2
−0.3
Income tax $B
0.0
0.0
0.0
Net income $B
−0.1
−0.3
−0.3
EPS, diluted $
−3.22
−10.66
−13.24
Dividend / sh $
·
·
·
Payout %
·
·
·
ROE %
·
·
·
Shares out B
0.28
0.04
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
7 of 7
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed